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ABSTRACT
The pharmacological activation of the cannabinoid receptor type 2, CB2, has been 
shown to elicit anti-tumoral mechanisms in different cancer types. However, little is 
known about its endogenous role in tumor pathophysiology, and different studies 
have attributed pro-tumorigenic properties to this receptor. In a previous work, we 
showed that CB2 expression is a poor prognostic factor in colon cancer patients. 
Here we report that activation of CB2 with low doses of specific agonists induce cell 
proliferation and favor the acquisition of aggressive molecular features in colon cancer 
cells. We show that sub-micromolar concentrations of CB2-specific agonists, JWH-133 
and HU-308, promote an increase in cell proliferation rate through the activation of 
AKT/PKB pathway in colon cancer in vitro and in vivo. AKT activation promotes GSK3β 
inhibition and thus, a more aggressive cell phenotype with the subsequent elevation 
of SNAIL levels, E-cadherin degradation and β-catenin delocalization from cell 
membrane. Taken together, our data show that CB2 activation with sub-micromolar 
doses of agonists, which could be more similar to endogenous levels of cannabinoids, 
promote colon cancer progression, implicating that CB2 could have a pro-tumorigenic 
endogenous role in colon cancer.
INTRODUCTION
Based on incidence and mortality, colon cancer is 
the second leading cause of cancer death in developed 
countries and the fourth in the world, with more than one 
million new cases of colon cancer diagnosed each year 
[1, 2]. Despite considerable progress in recent decades 
in surgical oncology and the application of new radiation 
and chemotherapy treatments, mortality by colon cancer 
remains high due to metastasis and resistance to current 
treatments. Thus, understanding the mechanisms involved 
in the control of tumor growth and the development of 
chemopreventive agents and targeted therapies are major 
goals of basic research in oncology.
Cannabinoids, the active compounds obtained 
from Cannabis sativa and their derivatives, have been 
primarily used with palliative purposes in cancer 
patients. However, in recent years, those compounds 
(plant-derived or synthetically-produced) have been 
proposed for their use as anticancer agents since different 
studies have attributed them anti-tumoral effects such 
as induction of apoptosis, cell cycle arrest or inhibition 
of cell migration and angiogenesis [3, 4]. Cannabinoids 
exert their effects through the endogenous system called 
endocannabinoid system (ECS). ECS is comprised of two 
major cannabinoid-specific receptors, CB1 and CB2; along 
with the endocannabinoids anandamide (AEA) [5] and 
2-arachidonoylglycerol (2-AG) [6, 7] and the enzymes 
that carry out their biosynthesis and degradation. There 
exist other receptors that have also been proposed as 
endocannabinoid receptors, the transient receptor potential 
cation channel subfamily V member 1 (TRPV1) or the 
orphan G protein-coupled receptor (GPR55) [8]. The CB1 
receptor is mainly present in the central nervous system 
and so mediates the psychotropic effects of exogenous 
cannabinoids, whereas the CB2 receptor is mainly 
expressed in peripheral and inflammatory tissues [9]. It is 
described that the ECS undergoes adaptive changes during 
tumor development, which are in general an increase in 
endocannabinoid and cannabinoid receptors expression 
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levels and a decrease in the levels of the enzymes 
responsible for endocannabinoid degradation (i.e. FAAH), 
although there can be some exceptions specific to tumor 
types [4]. Specifically for colorectal cancer, an increase 
in endocannabinoid levels, a down-regulation of CB1 and 
an up-regulation of CB2 receptor expression is described 
[10–12].
Several evidences points to the cannabinoid receptor 
CB2 as a target for anti-tumoral therapy in several types of 
cancer [3, 4, 12–14], but little is known about its role in 
tumor generation and progression. In fact, a contradictory 
role for the ECS in cancer pathophysiology is currently 
being discussed, with some works reporting anti-tumoral 
effects of cannabinoids, and others pointing to a possible 
tumor-promoting and immunosuppressive role [15–20]. 
Besides, some reports show that the EC50 values of 
exogenous administered cannabinoid drugs, usually in 
the micromolar range, may not reflect the endogenously 
produced endocannabinoids levels, which reach at 
most nanomolar concentration locally [21]; therefore 
physiological effects could differ from pharmacological 
ones [15, 21]. Moreover, Hart et al. demonstrated that 
THC levels comparable to those found in serum of patients 
that underwent THC treatment accelerated the proliferation 
of cancer cells [20]. This suggests that cannabinoids action 
on tumor progression is strongly dose-dependent, and a 
bimodal action it is possible with low (endo)cannabinoid 
levels being pro-proliferative and high doses of exogenous 
agonists being anti-proliferative and pro-apoptotic [15]. 
Thus, a deeper knowledge of the physiological role of 
CB2 in the relevant processes of cancer development, 
such as cell survival and proliferation, is necessary before 
proposing CB2 agonists as anti-tumoral drugs.
The aim of this study was to investigate on in vitro 
and in vivo murine model whether CB2 receptor activation 
with a wide range of doses of agonist results in pro-
tumoral effects and, in this case, to identify the possible 
molecular mechanisms underlying this oncogenic action. 
In particular, we explored the hypothesis that cannabinoid 
receptor activation might induce pro-proliferative effects 
through the activation of PI3K/AKT survival pathway.
RESULTS
Biphasic effect of synthetic cannabinoids, JWH-
133 and HU-308, on proliferation of colon cancer 
cells
We first analyzed the effect of different doses of 
specific synthetic CB2 agonists on cell proliferation with 
the colon cancer derived cell line HT29. Cells were 
incubated in the presence of increasing concentrations 
of JWH-133 or HU-308 for 48h, and cell viability was 
evaluated by CCK-8 viability assay and by flow cytometry.
As shown in Figure 1A and 1B the proliferation 
increased until 1 μM concentration, while 10 μM decreased 
cell survival; resulting in a biphasic proliferation curve. 
Similar results were obtained with JWH-133 in SW480 
and LS174T cell lines (Supplementary Figure S1A), 
verifying that it was not a cell-specific effect. However, 
the effects were more evident with HT29 cell line, so 
most of the experiments were performed with this cell 
line. The blockade of CB2 with the antagonist SR 144528 
(SR2) verified that the effect is CB2-mediated since the 
increase in cell proliferation with JWH-133 0.1 or 1 μM is 
prevented by co-incubation with SR2 0.5 μM (Figure 1C, 
Supplementary Figures S1B and S1C).
To study the effect of JWH-133 on apoptosis and 
to discard a toxic effect of the vehicle (DMSO), we 
performed an Annexin V-FITC/IP staining in HT29 cells. 
We observed no significant differences in cell death 
between different doses (Figure 2A), therefore the increase 
in cell viability is due to an increase in proliferation and 
not to a reduced survival in control samples rescued 
by JWH-133 treatment. Besides, a cell-cycle analysis 
demonstrated that cannabinoid treatment resulted in a 
moderate, although repeated and significant accumulation 
of cells in G2/M phase (Figure 2B) at 0.1 and 1 μM of 
JWH-133. These results suggested that the agonist could 
be inducing faster progression of the cell cycle and thus 
an increase in cell division. Moreover, we observed 
that 10 μM of JWH-133 did not trigger apoptosis, since 
no significant changes were detected (Figure 2A), but 
promoted an increase of cells in G0/G1 phase (Figure 2B); 
which suggest that it is inducing a cytostatic, instead of a 
cytotoxic, effect.
Since the maximal increase in proliferation was 
reached at JWH-133 0.1 μM in HT29 cells, we decided to 
carry out the subsequent studies with this stimuli.
PI3K/AKT signaling pathway is activated after 
JWH-133 treatment
It has been previously reported that G protein-
coupled receptors (GPCRs), the family of receptors to 
which CB2 belongs, can stimulate the serine/threonine 
protein kinase AKT/PKB (Protein Kinase B) activity [22]; 
which is a signal transduction pathway that promotes 
tumorigenesis by stimulating cell cycle progression, 
proliferation and activating anti-apoptotic mechanisms 
[23]. Therefore, we hypothesized that AKT pathway may 
be involved in the increase on cell proliferation triggered 
by JWH-133.
As shown in Figure 3A, JWH-133 enhanced AKT 
phosphorylation in HT29 cells in a time dependent 
manner, reaching the maximal levels at 18h and 48h. 
The involvement of the PI3K/AKT cascade in CB2 
agonist-mediated enhancement of cell proliferation was 
further tested by examining the phosphorylated levels 
of a downstream target, the glycogen synthase kinase-
3β (GSK3β). Treatment with JWH-133 leads to AKT-
mediated phosphorylation of GSK3β, which levels are 
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increased in a time-dependent manner and reached the 
highest levels at 48h (Figure 3A). Additionally, we 
verified that AKT activation is involved in the JWH-
133 induced cell proliferation, as its blockade with a 
specific inhibitor (iAKT) prevented the increase in cell 
viability in HT29 cells (Figure 3B). Similar results were 
obtained with SW480 and LS174T cell lines, verifying 
that AKT activation is involved and necessary for the pro-
proliferative effects of low concentration of JWH-133 
(Supplementary Figures S1B, S1C and S2).
GSK3β inactivation through CB2 signaling leads 
to an increase in SNAIL levels
GSK3β is a serine/threonine protein kinase 
constitutively active in unstimulated cells, but its 
phosphorylation by p-AKT leads to its inactivation 
[23]. This kinase is not only involved in the control of 
cell proliferation, but it is described that it is also related 
with the epithelial-mesenchymal transition (EMT), the 
first step in the metastatic process. Concretely, GSK3β 
reduces the stability of SNAIL, a zinc-finger transcription 
factor implied on the initiation of the EMT, by inducing 
it degradation [24]. We observed a significant increase in 
SNAIL protein levels in HT29 cells stimulated with JWH-
133 0.1 μM that correlated with the increment of p-AKT 
and p-GSK3β levels (Figure 3A)
We confirmed that the increase in p-AKT, p-GSK3β 
and SNAIL levels were CB2-specific and that AKT 
activation is key for the downstream effects, since CB2 
and AKT blockade with specific inhibitors (SR2 and 
iAKT, respectively) prevented the enhancement of 
p-AKT, p-GSK3β and SNAIL levels induced byJWH-133 
(Figure 4 and Supplementary Figure S2).
Figure 1: Biphasic effect of CB2 agonists on colon cancer cell line. A. HT29 cells were incubated with increasing concentrations 
of JWH-133 or B. HU-308 for 48h and cell viability was assayed with CCK-8. C. HT29 cells were incubated with 0.1 or 1 μM JWH-133 for 
48h in the presence or absence of 0.5 μM CB2 antagonist, SR 144528 (SR2). Control JWH-133 group, DMSO; Control in JWH-133+SR2, 
0.5 μM SR2. Data are the means ± s.e. of two different experiments, each performed with six replicates. *p < 0.05 and **p < 0.01 using 
Student’s t-test for the comparison between vehicle-treated and cannabinoid-treated cells; and #p < 0.05 and ##p < 0.01 for the comparison 
between cannabinoid-treated and antagonist-treated cells.
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Membrane-bound E-cadherin loss after JWH-
133 treatment and disassembly of cell-cell 
contacts
Since SNAIL stabilization could suggest the 
initiation of EMT, we proceeded to study the state of 
the cell-cell interactions, which are primarily affected 
in this process. E-cadherin is one of the most important 
molecules in the maintenance of cell interactions by 
forming the adherens junctions (AJs) in the cell surface. 
Due to SNAIL is a well-described repressor of E-cadherin 
transcription, we evaluated mRNA levels of E-cadherin, 
but we did not find differences due to JWH-133 treatment 
(data not shown). However, we evaluated changes in 
protein by western blot, and we found a slight but repeated 
decrease in E-cadherin levels at 48h (Figure 3A), that 
was prevented by the blockade of CB2 and AKT with the 
specific inhibitors (Figure 4A).
As E-cadherin has to be membrane-attached to 
maintain cell-cell interactions, we analyzed by confocal 
microscopy the localization of this protein after treatment 
with JWH-133 0.1 μM. It can be observed in Figure 5A 
that E-cadherin remains unaffected in control, showing 
membrane location; while after 24h of treatment suffers 
a delocalization from membrane to cytoplasm. After 48h 
of treatment, E-cadherin has nearly disappeared from 
the whole cell cluster in many of the analyzed fields. 
This could suggest that E-cadherin could be suffering 
some post-transcriptional modification that induce 
its disassembling from cell surface and its posterior 
degradation, but the levels of SNAIL, although are 
elevated, might not be enough to trigger E-cadherin 
transcriptional repression.
In AJs E-cadherin binds through its cytoplasmic 
domain to different proteins, one of them β-catenin. 
Upon E-cadherin degradation, β-catenin remains free in 
cytoplasm and, in normal conditions, it is degraded by 
a complex that includes GSK3β. However, if β-catenin 
cannot be degraded it is transported to the nucleus 
where it exerts a signaling function by promoting the 
transcription of genes related with cell proliferation [25, 
26]. As we have seen E-cadherin degradation and GSK3β 
inactivation, we decided to investigate whether β-catenin 
is transported to the nucleus where it would promote the 
transcription of genes that contribute to cell proliferation. 
By confocal microscopy we observed that after 48h of 
Figure 2: A. Evaluation of apoptosis by Annexin V-FITC/IP staining. Representative plots of Annexin V-FITC/IP staining of HT29 cells 
cultured in the presence of increasing concentrations of JWH-133 for 48h, including the percentage of early apoptotic cells (bottom right 
quadrant) and late apoptotic cells (upper right quadrant). B. Cells were incubated in the presence of increasing concentrations of JWH-133 
for 48h and cell cycle was assayed by flow cytometry. Data are the means ± s.e. of three different experiments. *p < 0.05 using Student’s 
t-test for the comparison between vehicle-treated and cannabinoid-treated cells.
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treatment with JWH-133 at 0.1 μM, in accordance with 
E-cadherin degradation, β-catenin is internalized from 
the membrane into the cytoplasm and nucleus, without 
changes in total levels (Figure 5B).
Altogether, these data suggest that CB2 stimulation 
with sub-micromolar doses of the agonist lead to the 
activation of PI3K/AKT signaling axis, and to the increase 
in tumor cell proliferation and aggressiveness.
Differential response of colon cancer xenografts 
to diverse doses of JWH-133 in nude mice
To asses our hypothesis in an in vivo model, 
subcutaneous tumors were generated in nude mice with 
HT29 cells. Tumor-bearing animals were treated daily 
with the vehicle, 1 mg/kg JWH-133 or 5 mg/kg JWH-133 
for 14 days. Tumor volume was calculated every day, and 
at the end of the experiment tumors were dissected. As 
shown in Figure 6A, tumors increased their growth rate 
significantly in response to 1 mg/kg of JWH-133 with 
respect to the vehicle-treated group; whereas a 5 mg/kg 
of JWH-133 produced the opposite effect, a reduction 
in tumor growth rate (although significant effect is only 
observed at day 14).
In agreement to our in vitro results, we observed 
significant higher p-AKT levels in the 1 mg/kg-treated 
group respect to the vehicle- or 5 mg/kg-treated groups 
(Figure 6B). However, in the 5 mg/kg-treated group 
Figure 3: Signaling mechanisms activated by JWH-133 0.1 μM in HT29 cells. A. Cells were incubated for different times with 
0.1 μM of JWH-133 in serum-free medium. The phosphorylation of AKT and GSK3β, and SNAIL and E-cadherin levels were analyzed 
in the cells by western blot (WB) analysis using the indicated specific antibodies. Representative blots of three different analyses are 
shown (left). Densitometric analysis of AKT and GSK3β phosphorylation levels was performed with ImageJ (NIH) software and data 
are represented as the means ± s.e. of three different experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 using Student’s t-test for the 
comparison between vehicle-treated and cannabinoid-treated cells (right). B. HT29 cells were incubated with 0.1 or 1 μM JWH-133 for 
48h in the presence or absence of 0.5 μM AKT inhibitor, iAKT 1/2 (iAkt) and cell viability was assayed with CCK-8. Control JWH-133 
group, DMSO; Control in JWH-133+iAkt, 0.5 μM iAkt. Data are the means ± s.e. of three different experiments, each performed with six 
replicates. *p < 0.05 using Student’s t-test for the comparison between vehicle-treated and cannabinoid-treated cells; and #p < 0.05 and ##p 
< 0.01 for the comparison between cannabinoid-treated and iAkt-treated cells.
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p-AKT levels are higher (although not significant) than 
in the vehicle-treated one, which could be because the 
bioavailability of JWH-133 may vary in different areas of 
the tumor, leading to intra-tumoral variability of the effect.
DISCUSSION
Despite the controversy about the role of the 
endocannabinoid system (ECS) in tumor generation and 
progression, there is increasing evidence that shows that 
the ECS might play a pro-tumorigenic role [4, 15, 18, 
28, 29]. Indeed, in a previous study we demonstrated 
that CB2 expression correlates with worse overall and 
disease free survival in colon cancer patients, setting it as 
a poor prognostic factor for those patients [30]. Here we 
show that the activation of the CB2 receptor with doses 
of exogenous agonists, JWH-133 and HU-308, below the 
micromolar range promotes cell proliferation in colon 
cancer derived cell lines. We observed a biphasic effect on 
proliferation of HT29, SW480 and LS174T where agonist 
concentrations below 1 μM promote cell growth while a 
10 μM dose is necessary to produce cytostatic effects by 
arresting cell cycle in G0/G1 phase. It has been recently 
described that the bimodal response to cannabinoids 
through CB2 receptor can be due to the existence of 
CB2-GPR55 heteromers, and that low doses of agonists 
(THC, in this case) activate CB2 exclusively, leading to 
pro-tumoral actions; but higher doses of THC also binds 
to GPR55 and exerts a cross-antagonism that inhibits 
CB2 pro-proliferative signaling [27]. It can be interesting 
in future studies to analyze the presence of CB2-GPR55 
heteromers in our colon cancer model to shed light on 
the mechanisms underlying the biphasic effect of CB2 
agonists.
As the molecular mechanisms underlying both 
pro- and anti-tumoral effects of CB2 activation are not 
Figure 4: Inhibition of AKT/PKB and GSK3β phosphorylation, and SNAIL stabilization by the CB2 antagonist, SR2; 
and the AKT inhibitor, iAkt. A. HT29 cells were pre-incubated with 0.5 μM SR2 (left panel) or 5 μM iAkt (right panel) for 5h prior to 
be incubated for 24h and 48h with JWH-133 0.1 μM in presence or absence of 0.5 μM SR2 or 0.5 μM iAkt. Representative blots of three 
different analyses are shown. B. Densitometric analysis of SNAIL was performed with ImageJ (NIH) software and data are represented as 
the means ± s.e. of three different experiments. *p < 0.05 and **p < 0.01 using Student’s t-test for the comparison between vehicle-treated 
and cannabinoid-treated cells.
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well-described yet, we decided to study in depth those 
mechanisms. We found that JWH-133, with a dose that 
has previously shown to promote the highest proliferation 
levels in HT29, increased AKT phosphorylation in 
a CB2-specific manner. As a consequence, p-AKT 
phosphorylated the glycogen synthase kinase-3β (GSK3β), 
Figure 5:  Regulation of E-cadherin and β-catenin localization and stability by JWH-133 0.1 μM treatment. HT29 cells 
were incubated with JWH-133 0.1 μM for 24h and/or 48h in serum-free medium. Cells were stained with specific A. E-cadherin (green) or 
B. β-catenin (green) antibodies and photographed with confocal microscopy. Nuclei were stained with Topro-3 (blue). Scale bars, (A) 55μm 
and (B) 50μm. Representative image of three different experiments.
Figure 6: In vivo effects of JWH-133. Nude mice were injected s.c. in the right flank with HT29 cells and a week later (day 1) were 
treated for 14 days with vehicle (control, DMSO), 1 mg/kg JWH-133 or 5 mg/kg JWH-133. Treatments were carried out by intraperitoneal 
injections every day. Tumor volumes were measured daily. A. Tumor growth curve after administration of vehicle (circles), 1 mg/kg JWH-
133 (squares) or 5 mg/kg JWH-133 (triangles). Results represent the mean ± s.e. of five mice in each group. *p < 0.05 and **p < 0.01 
using two-way ANOVA with a Student-Newman-Keuls test post hoc analysis. B. Western blot analysis and C. densitometric analysis of 
phospho-AKT in tumors from the three different mice groups. Results represent the mean±s.e. of p-AKT levels of five mice in each group, 
**p < 0.01 using Student’s t-test for the comparison between vehicle-treated and cannabinoid-treated groups.
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leading to its inactivation. GSK3β is constitutively active 
in unstimulated cells and acts as a “tumor suppressor” 
since maintains in inactivate state different molecules 
related to cell growth, such as cyclin D1 or c-Myc [23, 
31]. GSK3β is also involved in SNAIL degradation [32], 
so as a consequence of its inactivation after JWH-133 
treatment, we observed an increase in SNAIL protein 
levels. Despite SNAIL is a transcriptional repressor of 
E-cadherin we did not find a decrease in their mRNA 
levels in response to increased levels of SNAIL. 
However, since we observed decrease of E-cadherin 
protein levels and its delocalization from the membrane, 
we hypothesized that these effects might be mediated by 
a post-transcriptional regulation that finally destabilize 
the cell-cell interactions [25]. These results could be 
in agreement with previous studies showing that upon 
activation of Src tyrosine kinase, which could occur 
during EMT, adherens junctions are destabilized due to 
E-cadherin phosphorylation, which is then internalized 
and finally degraded in the lysosome [25, 33]. Further 
studies are necessary to unveil the mechanism that leads 
to E-cadherin degradation after CB2 activation with low 
doses of agonists. Nevertheless, the destabilization of 
E-cadherin from membrane was verified because β-catenin 
was released from cell membrane and internalized into 
the intracellular and nuclear space. In normal conditions, 
the released β-catenin would be degraded through a 
complex that involves the adenomatous polyposis coli 
(APC)-complex consisting of APC, axin, diversin, casein 
kinase I, and GSK3β. However, the lack of function of 
any of these components, such as GSK3β, prevents 
β-catenin degradation [34]. In these conditions, β-catenin 
is transported to the cell nucleus where it binds to T-cell 
factor/lymphoid enhancer factor (TCF/LEF) DNA binding 
proteins, which regulate transcription of genes such as 
c-Myc or cyclin D1 [35]. Since GSK3β is inhibited due 
to JWH-133 stimulation, the released β-catenin, instead 
of being degraded, is internalized into the cytoplasm and 
nucleus, where it could be exerting pro-tumoral actions. 
Besides, β-catenin stabilization is also influenced because 
the HT29 cell line possess a truncated form of APC, which 
is a typical characteristic in colon cancer, and it is only 
partially active; so the degradation of the free cytoplasmic 
β-catenin is less efficient compared to cells possessing the 
wild type form of this protein [36].
Finally, our in vivo model further confirmed that 
the effect on cell proliferation is strongly dependent on 
cannabinoid concentrations. While a dose of 5 mg/kg 
of JWH-133 decreased the tumor proliferation rate, a 
dose of 1 mg/kg significantly increased it. Moreover, in 
agreement with the previous in vitro study, the group with 
the higher proliferation rate has greater levels of p-AKT. 
This strengthens our hypothesis that CB2 activation with 
a low dose range of agonists leads to an increase of 
proliferation and pro-tumoral effect by activation of PI3K/
AKT signaling pathway.
In conclusion, the present study shed light on the 
physiological contribution of CB2 to cell functions relevant 
for cancer progression, since the activation of CB2 with 
doses that are not capable of triggering apoptosis, below 
the micromolar range, increases the proliferation and 
aggressiveness on colon cancer cell lines. These results 
have to be taken into account when a cannabinoid-based 
therapy is being considered for colon cancer patients due 
to the concentration-dependent response and the difficulty 
for the tumor-site delivery of cannabinoid-derived drugs.
MATERIALS AND METHODS
Reagents and drugs
JWH-133 and HU-308 were purchased from Tocris 
Cookson (Bristol, UK), and the CB2 antagonist SR 
144528 was from Cayman Chemical (Ann Arbor, MI). 
The drugs were dissolved in dimethylsulfoxide (DMSO). 
Antibody anti-phospho-AKT (Ser473), anti-total-AKT 
and anti-phospho-GSK3β (Ser9) were obtained from 
Cell Signaling Technology (St Louis, MO, USA). We 
purchased antibodies anti-SNAIL, anti-β-Actin, and AKT 
Inhibitor (AKTi-1/2) from Abcam (Cambridge, UK). 
Anti-E-cadherin antibody is from Becton Dickinson (San 
Jose, CA, USA) and anti-β-catenin antibody is from Dako 
(Glostrup, Denmark).
Cell culture
Human colon carcinoma cells HT29, SW480 and 
LS174T were purchased from American Type Culture 
Collection (Rockville, MD, USA) and were cultivated 
Dulbecco’s modified Eagle medium (DMEM) (Gibco 
Life Technologies, Gergy-Pontoise, France), containing 
10% heat-inactivated fetal calf serum (FCS), 2mM 
L-glutamine, penicillin (100 U/mL), streptomycin (100 
ng/mL) and fungizone (0.25 μg/mL) at 37ºC in a 5% CO2-
humidified atmosphere. The cell lines were authenticated 
by STR DNA profiling analysis. Cells were seeded sub-
confluently and, before the experiments, the serum was 
removed overnight. For the studies with the CB2 antagonist 
(SR2) and AKT inhibitor (iAKT), cells we pre-incubated 
with SR2 0.5 μM or iAKT 5 μM alone for 5h, after that 
the medium was replaced with medium containing JWH-
133 at the indicated concentration with 0.5 μM SR2 or 0.5 
μM iAKT.
Cell viability assays
Cells were set up 4x103 cells per well of a 96-well 
plate and were cultured in DMEM medium supplemented 
with 10% FCS overnight. The medium was replaced for 
serum-free DMEM medium and cells were incubated for 
48h with the treatments according to figure legends. Cell 
viability was assayed by Cell Counting Kit-8 (CCK-8) 
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(Dojindo EU GmbH, Munich, Germany) according to the 
manufacturer’s protocol.
Flow cytometry
Flow cytometry was used to detect apoptotic cells 
and the distribution of cell cycle. 3x105 cells were seeded 
per well of a 6-well plate. After being cultivated with 
medium alone or medium containing the indicated stimuli 
for 48h, cells were harvested. To analyze apoptosis by 
Annexin V/PI (Propidium Iodure) staining, the cells were 
washed twice with PBS and incubated in 0.1 ml of binding 
buffer 1x with 5μL Annexin V-FITC for 15 min. Then 
5μL of PI were added and finally cells were suspended 
in a final volume of 0.3 ml of binding buffer 1x. For cell 
cycle distribution analysis, the cells were washed twice 
with PBS and fixed overnight at 4ºC with cold 100% 
ethanol. After eliminating and washing ethanol, cells were 
incubated overnight in 0.3 ml of PBS with 0.2 mg/ml 
Rnase and 0.02 mg/ml PI. In both, 20 000 cells of each 
sample were analyzed by flow cytometry in a MACSQuant 
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Western blot analysis
Cells were cultured at 3x105 cells per well of 
a 6-well plate and incubated with the treatment and 
times described in the Results section. Cells were lysed 
into T-PER buffer supplemented with proteases and 
phosphatases inhibitors 1x. Protein concentration was 
determined using the Pierce BCA protein assay kit (Life 
Technologies, Carlsbad, CA). Proteins were separated in 
SDS-PAGE and blotted on Nitrocellulose membranes. 
Blots were incubated overnight in 4ºC with the following 
antibodies: anti-E-cadherin (1/1500), anti-phospho-AKT 
(1/2000), anti-total-AKT (1/1000), anti-phospho-GSK3β 
(1/1000), anti-SNAIL (1/500) and anti-β-Actin (1/2000) as 
loading control. The next day, blots were incubated 1 hour 
at room temperature with goat anti-rabbit or anti-mouse 
IRDye800® and IRDye700DX® conjugated secondary 
antibodies (Rockland, Limerick, PA). Densitometric 
analysis was done with Image-J (NIH).
Confocal microscopy
Cells were set up 5x104 cells per well of a 4-well 
Nunc™ Lab-Tek™ II Chamber Slide™ System 
(Thermoscientific, Waltham, MA) and treated for 24h 
and 48h with JWH-133 0.1 μM, when necessary. After 
treatment, cells were fixed with Methanol for 10 minutes, 
washed with PBS, incubated in 50 mM NH4Cl and 
blocked with 5% BSA to reduce non-specific protein 
binding. Cells were incubated with Anti E-Cadherin (1/25) 
or Anti β-catenin (ready-to-use) overnight at 4ºC, washed 
with PBS and followed with Alexa Fluor 488 anti-mouse 
(Invitrogen Life Technologies, 1/1000) for 45 minutes 
at room temperature. Nuclei were stained with Topro-3 
(Invitrogen Life Technologies, 1/500) for 20 minutes. 
The chambers were removed from the glass slide and 
cells were visualized with inverted Microscopy. Images 
of the specimens were collected with a TCS SP5 confocal 
microscope (Leica Microsystems, Wetzlar, Germany), 
equipped with 10×0.22 and at an optical zoom of 3. 
Z-series images were obtained through the collection of 
serial, confocal sections at 1 μm intervals.
In vivo xenograft model
All animal studies were conducted in accordance 
with the Spanish institutional regulation for the housing, 
care and use of experimental animals, have been 
carried out with ethical committee approval and met 
the European Community directives regulating animal 
research. Recommendations made by the UKCCCR have 
been adhered to carefully. Swiss nude (nu/nu) 5-week-
old female mice were purchased from Charles River 
(Chatillon-sur-Chalaronne, France) and were housed in 
a laminar airflow cabinet under pathogen-free conditions 
on a 12-h light–dark schedule. Mice were injected 
subcutaneously (s.c.) in the right flank with 5x106 HT29 
cells in 0.1 ml of PBS. One week after transplantation, 
mice were divided into three experimental groups of five 
animals each, which received the following treatments 
as intraperitoneal (i.p.) injections: group 1, 5% DMSO 
(control); group 2, 1 mg/kg body weight (b.w.) JWH-
133; group 3, 5 mg/kg b.w. JWH-133. The injection was 
repeated every day and treatment was continued for 14 
days. Tumor volumes were monitored every day using 
calliper measurements and were calculated using the 
following formula: (4π/3) × (w/2)2 × (l/2), where w = width 
and l = length. At the end of the treatment, animals were 
sacrificed, and tumors were dissected and divided into 
pieces, which were cryoembedded in cryo-preservative 
O.C.T compound (Tissue-Tek) or paraffin-embedded for 
further analysis. Protein extraction from dissected sample 
was performed with T-PER buffer supplemented with 
proteases and phosphatases inhibitors 1x (1g tissue/10 mL 
buffer) as above described.
Statistical analysis
Data are presented as mean ± s.e. (standard error) 
of the number of experiments indicated. Statistical 
comparisons among groups were made with Student’s 
t-test, and the difference was considered to be statistically 
significant when the p-value was < 0.05.
Tumor growth curves in mice xenograft model were 
compared by two-way ANOVA with a post hoc analysis 
by Student-Newman-Keuls test with Graph-Pad Prism 
6 software.
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